reports
Interpace Biosciences Announces Second Quarter 2025 Financial and Busi...
Interpace Biosciences Announces Second Quarter 2025 Financial and Business Results ●Q2 Revenue of $9.2 million ●Q2 Cash Collections of $10.8 million ●Q2 Thyroid test volume up 16% year-over-year to record levels ●Q2 Thyroid revenue of $8.7M; up 25% year-over-year to record levels PARSIPPANY, NJ, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the second quarter ended June 30, 2025 and provided a business and financial update. Second quarter Net Revenue was $9.2 million. Loss from continuing ...
Interpace Biosciences Announces First Quarter 2025 Financial and Busin...
Interpace Biosciences Announces First Quarter 2025 Financial and Business Results ●Q1 Revenue of $11.5 million; a 13% increase year-over-year ●Q1 Cash Collections of $11.3 million; a 10% increase year-over-year to record levels ●Q1 Thyroid test volume up 16% year-over-year to record levels ●Q1 Thyroid revenue of $8.0M; up 19% year-over-year to record levels ●Initiates Full Year 2025 Revenue Guidance of approximately $38 million PARSIPPANY, NJ, May 08, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for...
Effective May 2, 2025, Interpace Diagnostics® Will No Longer Accept Sp...
Effective May 2, 2025, Interpace Diagnostics® Will No Longer Accept Specimens for PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk Interpace Expects to Remain Profitable as a Thyroid-focused Business PARSIPPANY, NJ, April 24, 2025 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that the Genetic Testing for Oncology (L39365) Local Coverage Determination (LCD) issued by the Medicare Administrative Contractor Novitas Solutions will go into effect, ending reimburs...
Interpace Biosciences Announces Preliminary Full-year and Fourth Quart...
Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2024 Financial and Business Results ●Q4 and FY Test volume increase 21% and 17% year-over-year ●Q4 and FY Volume, Revenue, and Profitability at all-time record levels PARSIPPANY, NJ, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced preliminary financial and business results for the fiscal year and fourth quarter ended December 31, 2024. Fourth quarter Molecular Volume increased 21% year-over-year compared to Q4 2023, and 17% for the Full ...
PancraGEN® Will Continue to be Offered While Interpace Re-evaluates it...
PancraGEN® Will Continue to be Offered While Interpace Re-evaluates its Previously Announced Re-structuring Plan PARSIPPANY, NJ, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, (“Interpace” or the “Company”) (OTCQX: IDXG) today announced notification that the Centers for Medicare & Medicaid Services (CMS) directed its Medicare Administrative Contractors, Novitas and First Coast Service Options, Inc., to delay implementation of the Genetic Testing for Oncology Local Coverage Determination (LCD) (L39365), from February 23, 2025, to April 24,...
Effective 02/07/2025, Interpace Diagnostics® to No Longer Offer Pancra...
Effective 02/07/2025, Interpace Diagnostics® to No Longer Offer PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk PARSIPPANY, NJ, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, (“Interpace” or the “Company”) (OTCQX: IDXG) today responded to the final Local Coverage Determination (LCD) of Genetic Testing for Oncology (L39365) issued by the Centers for Medicare & Medicaid Services (CMS). The new LCD establishes non-coverage for the Company’s widely used PancraGEN® test. PancraGEN is a DNA-based diagnostic mo...
Interpace Biosciences Announces Record Third Quarter 2024 Financial an...
Interpace Biosciences Announces Record Third Quarter 2024 Financial and Business Results ●Q3 Revenue of $12.3 million; a $3.2M and 35% increase year-over-year ●Q3 Test volume up 26% year over year to record levels ●Q3 Cash collections of $11.3M; a $1.4M and 15% increase year-over-year ●Q3 Volume, Revenue, and Profitability at all-time record levels PARSIPPANY, NJ, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the third quarter ended September 30, 2024 and provided a business and financia...
Interpace Biosciences Announces Capital Restructuring of Its Preferred...
Interpace Biosciences Announces Capital Restructuring of Its Preferred Stock as a First Step Toward Seeking an Uplisting of Its Common Stock to Nasdaq PARSIPPANY, NJ, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that its Series B Preferred Stock investors, Ampersand Capital Partners and 1315 Capital (the “Investors”), have exchanged (the “Exchange”) their existing Series B Preferred Stock for a new issuance of Series C Preferred Stock in order to assist the Company in seeking an uplisting of its Common Stock to ...
Interpace Biosciences Announces Record Second Quarter 2024 Financial a...
Interpace Biosciences Announces Record Second Quarter 2024 Financial and Business Results ●Q2 Revenue of $12.0 million; a $1.0M and 9% increase year-over-year ●Q2 Test volume up 12% year-over-year to record levels ●Q2 Cash collections of $11.0M; a $0.7M and 7% increase year-over-year ●Q2 Volume, Revenue, and Profitability at all-time record levels PARSIPPANY, NJ, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the second quarter ended June 30, 2024 and provided a business and financial update...
Interpace Diagnostics® Announces Undefined Extension of Medicare Cover...
Interpace Diagnostics® Announces Undefined Extension of Medicare Coverage for PancraGEN®, a Molecular Diagnostic Test That Assesses Cancer Risk of Pancreatic Cysts PARSIPPANY, NJ, July 29, 2024 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, (“Interpace” or the “Company”) (OTCQX: IDXG) today responded to the undefined extension granted by Centers for Medicare & Medicaid Services (CMS) to Novitas, its Medicare Administrative Contractor (MAC). Novitas announced late last week that CMS granted an extension to the final decision for Local Coverage Determin...
Interpace Diagnostics Announces New Data Analyzing Imbalance of Short ...
Interpace Diagnostics Announces New Data Analyzing Imbalance of Short Tandem Repeat Alleles for Pancreatic Cancer Detection Published as an ASCO 2024 Abstract PARSIPPANY, NJ, June 04, 2024 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences® (OTCQX: IDXG), is proud to announce that new data demonstrating the application of advanced sequencing technologies in pancreatic cancer was published as an e-abstract as part of the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Abstract e16359 () highlights the evolving landscape of sequencing techno...
Interpace Biosciences Announces First Quarter 2024 Financial and Busin...
Interpace Biosciences Announces First Quarter 2024 Financial and Business Results ●Q1 Revenue of $10.3 million; a 4% increase year-over-year ●Q1 Test volume up 10% year over year to record levels PARSIPPANY, NJ, May 09, 2024 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the first quarter ended March 31, 2024 and provided a business and financial update. First quarter Net Revenue was $10.3 million. Operating expenses for the first quarter were approximately 2% lower than the same period of 2023. ...
Interpace Biosciences Announces Preliminary Full-year and Fourth Quart...
Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2023 Financial and Business Results ●Q4 and FY Revenue of $10.3 million and $40.2 million; a $8.4 million and 26% increase year-over-year ●Q4 and FY Income from Continuing Operations of $0.8 million and $1.1 million; a $7.0 million and 119% increase year-over-year ●Q4 and FY Adjusted EBITDA of $1.5 million and $5.4 million; a $6.6 million and 463% increase year-over-year ●Q4 and FY Cash collections of $10.2 million and $40.4 million; a $9.0 million and 29% increase year-over-year ●Q4 and FY Volume, Revenue, and Profit...
Interpace Biosciences Announces Record Third Quarter 2023 Financial an...
Interpace Biosciences Announces Record Third Quarter 2023 Financial and Business Results ●Q3 Revenue of $9.1 million; an 11% increase year-over-year ●Q3 Test volume up 11% year-over-year ●Q3 Reimbursement improvement up 11% year-over-year, driven by additional commercial contracts and collection initiatives PARSIPPANY, NJ, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the third quarter ended September 30, 2023 and provided a business and financial update. Third quarter Net Revenue wa...
Interpace Biosciences Announces Record Second Quarter 2023 Financial a...
Interpace Biosciences Announces Record Second Quarter 2023 Financial and Business Results ●Q2 Revenue of $11.0 million; a 49% increase year-over-year; highest quarter in history ●Q2 Test volume up 15% year over year to record levels ●Q2 Reimbursement improvement up 34% year-over-year driven by additional commercial contracts and collection initiatives PARSIPPANY, NJ, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the second quarter ended June 30, 2023 and provided a business and financi...
Interpace Biosciences Releases Preliminary Record Second Quarter 2023 ...
Interpace Biosciences Releases Preliminary Record Second Quarter 2023 Business Results; Updates Status of PancraGEN® Reimbursement Q2 Revenue of $11 million; a 49.1% increase year-over-year and 12.2% better than Q1; highest quarter in history1st Half Revenue $20.9 million; 36.1% improvement over 1st Half 2022Q2 Test volume up 15.2% year-over-year to record levels; 1st Half volume up 16.5% year-over-yearNovitas announces that LCD L39365 has been rescinded and will NOT go into effect July 17, 2023 PARSIPPANY, NJ, July 10, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or...
Interpace Expects to Stop Offering PancraGEN® Test Due to CMS Decision...
Interpace Expects to Stop Offering PancraGEN® Test Due to CMS Decision to End Reimbursement as of July 17, 2023 PARSIPPANY, NJ, June 05, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that the Centers for Medicare & Medicaid Services (CMS) issued the final Local Coverage Determination (LCD) of Genetic Testing for Oncology (L39365) which establishes non-coverage for the Company’s widely used PancraGEN® test effective July 17, 2023. Commercially available in its current form since 2013, PancraGEN is a DNA-based molecular dia...
Interpace Biosciences Announces Record First Quarter 2023 Financial an...
Interpace Biosciences Announces Record First Quarter 2023 Financial and Business Results ●Q1 Revenue of $9.8 million; a 24% increase year-over-year; highest quarter in history ●Q1 Test volume up nearly 20% year over year to record levels ●Q1 41.9 million covered lives added, resulting from 8 new or updated commercial contracts PARSIPPANY, NJ, May 12, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the first quarter ended March 31, 2023 and provided a business and financial update. First quarter Ne...
Interpace Biosciences Announces Full Year and Fourth Quarter 2022 Fina...
Interpace Biosciences Announces Full Year and Fourth Quarter 2022 Financial and Business Results ●Q4 Revenue of $8.3 million ●Cash and Cash Equivalents total $4.8 million as of December 31, 2022 PARSIPPANY, NJ, March 27, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the fiscal year and fourth quarter ended December 31, 2022 and provided a business and financial update. Fourth quarter Net Revenue was $8.3 million. Operating expenses for the fourth quarter were approximately 22% lower than the sa...
Interpace Biosciences Announces Third Quarter 2022 Financial and Busin...
Interpace Biosciences Announces Third Quarter 2022 Financial and Business Results Sale of Pharma Significantly Improves Liquidity Resulting in Removal of Going Concern Q3 Revenue of $8.2 million up 2% versus Prior YearQ3 Adjusted EBITDA PositiveCash and Cash Equivalents total $6.3 million as of September 30, 2022 PARSIPPANY, NJ, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the third quarter ended September 30, 2022 and provided a business and financial update. Third quarter Net Revenu...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.